Patients With EGFR-Mutant NSCLC May Benefit from Targeted Therapy More Than Checkpoint Inhibitors
A recent retrospective, multicenter cohort study suggests osimertinib is more likely to benefit non-small cell lung cancer patients with EGFR mutations than alternative approaches, though prospective clinical trials are needed to confirm the findings. The Brigham’s Elio Adib, MD, a co-author of the study, discusses key takeaways.
Read More...